Longeveron to Present at H.C. Wainwright Conference

MIAMI, Sept. 03, 2026 /CourierPR/ -- Longeveron Inc., a clinical-stage regenerative medicine biotechnology company, will present at the H.C. Wainwright 28th Annual Global Investment Conference, set to take place from September 14 to 16, 2026, in New York City. The presentation will be available via webcast, accessible on the company’s website under the "Events and Presentations" section.

Longeveron focuses on developing regenerative medicines to address unmet medical needs. The company's lead product, laromestrocel (Lomecel-B®), is an allogeneic mesenchymal stem cell (MSC) therapy derived from the bone marrow of young, healthy adult donors. This therapy has shown potential in multiple mechanisms, including promoting vascular growth, regeneration, anti-inflammatory effects, and tissue repair, with applications across various disease areas.

Currently, Longeveron is pursuing four key pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease (AD), pediatric dilated cardiomyopathy (DCM), and aging-related frailty. The company has received significant regulatory recognition for its development programs, including Orphan Drug, Fast Track, and Rare Pediatric Disease designations for the HLHS program, and Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations for the AD program.

The presentation at the H.C. Wainwright conference is expected to highlight Longeveron’s advancements and future prospects in the field of regenerative medicine, providing investors and stakeholders with a comprehensive overview of the company’s strategies and achievements.